What is CYPH's current stock price?

CYPH (Cypherpunk Technologies Inc.) is currently trading at $1.28 with a market cap of $72.2M.

What sector is Cypherpunk Technologies Inc. in?

Cypherpunk Technologies Inc. (CYPH) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CYPH a good stock to buy?

Analysts have a Hold consensus on CYPH with a price target of $5.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CYPH Cypherpunk Technologies Inc.

Healthcare

$1.27+0.00%OpenMarket Cap: $72.2M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.39

P/S

0.00

EV/EBITDA

-2.07

DCF Value

$2.16

FCF Yield

-63.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-46.9%

ROA

-65.1%

ROIC

-35.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-77.2M	$—
Q4 null	$0.00	$40.2M	$—
FY null	$0.00	$4.8M	$—
Q3 null	$0.00	$-3.3M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$5.50

Target (Median)

$5.50

Target Range

$5.50 - $5.50

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Mirabelli Christopherdirector

SellMon Mar 30

Oei Khing Djiendirector

SellTue Mar 17

Oei Khing Djiendirector

SellTue Mar 17

Mirabelli Christopherdirector

SellTue Mar 17

Mirabelli Christopherdirector

SellTue Mar 17

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.10

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.

Peers

ICU